Parallel analysis of transcript and translation profiles: Identification of metastasis-related signal pathways differentially regulated by drug and genetic modifications

Journal of Proteome Research

Volumn 5, Issue 7, 2006, Pages 1555-1567

  Yang, Haiyan ^a   Yu, Li Rong ^b   Yi, Ming ^b   Lucas, David A ^b   Lukes, Luanne ^a   Lancaster, Mindy ^a   Chan, King C ^b   Issaq, Haleem J ^b   Stephens, Robert M ^b   Conrads, Thomas P ^b   Veenstra, Timothy D ^b   Hunter, Kent W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Biological association network; Isotope coded affinity tag; Metastasis; Microarray; Signaling pathway; Systems biology

Indexed keywords

CAFFEINE; STAT5 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BREAST TUMOR; CONTROLLED STUDY; DNA MODIFICATION; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; METASTASIS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA TRANSLATION; SCREENING TEST; SIGNAL TRANSDUCTION;

ANIMALS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSSES, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, INBRED DBA; MICE, INBRED STRAINS; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 33745823914     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr0504283     Document Type: Article

References (42)

1. Liotta, L. A.; Stetler-Stevenson, W. G. Principles of molecular cell biology of cancer: Cancer metastasis. In Cancer: Principles & Practice of Oncology, 4th ed.; DeVita, S. H. V., Rosenberg, S. A., Eds.; Lippincott Co.: Philadelphia, PA, 1993; pp 134-149.
2. Arslan, N.; Serdar, M.; Deveci, S. et al. Use of CA15-3, CEA, and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis. Ann. Nucl. Med. 2000, 14, 395-399.
3. Abner, A. L.; Collins, L.; Peiro, G. et al. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. Cancer 1998, 83, 2502-2508.
4. Eccles, S. A.; Box, G.; Court, W.; Sandle, J.; Dean, C. J. Preclinical models for the evaluation of targeted therapies of metastatic disease. Cell. Biophys. 1994, 24-25, 279-291.
5. Muschel, R. J.; Williams, J. E.; Lowy, D. R.; Liotta, L. A. Harvey ras induction of metastatic potential depends on oncogene activation and the type of recipient cell. Am. J. Pathol. 1985, 121, 1-8.
6. Hunter, K. W.; Broman, K. W.; Voyer, T. L. et al. Predisposition to Efficient Mammary Tumor Metastatic Progression Is Linked to the Breast Cancer Metastasis Suppressor Gene Brms1. Cancer Res. 2001, 61, 8866-8872.
7. Yang, H.; Rouse, J.; Lukes, L. et al. Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis. Clin. Exp. Metastasis 2005, 21, 719-735.
8. Hedenfalk, I.; Duggan, D.; Chen, Y. et al. Gene-Expression Profiles in Hereditary Breast Cancer. N. Engl. J. Med. 2001, 344, 539-548.
9. Scherf, U.; Ross, D. T.; Waltham, M. et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 2000, 24, 236-244.
10. Korn, E.; Troendle, J.; McShane, L.; Simon, R. M. Controlling the number of false discoveries: Application to high-dimensional genomic data. J. Statistical Planning and Inference 2005.
11. Simon, R.; Korn, E.; McShane, L.; Wright, G.; Zhao, Y. Design and Analysis of DNA Microarray Investigations; Springer-Verlag: New York, 2005.
12. Wright, G. W.; Simon, R. M. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003, 19, 2448-2455.
13. Yu, L. R.; Conrads, T. P.; Uo, T. et al. Evaluation of the acid-cleavable isotope-coded affinity tag reagents: application to camptothecin-treated cortical neurons. J. Proteome Res. 2004, 3, 469-477.
14. Le Voyer, T.; Lu, Z.; Babb, J. et al. An epistatic interaction controls the latency of a transgene-induced mammary tumor. Mamm. Genome 2000, 11, 883-889.
15. McShane, L. M.; Radmacher, M. D.; Freidlin, B. et al. Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. Bioinformatics 2002, 18, 1462-1469.
16. van't Veer, L. J.; Dai, H.; van de Vijver, M. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature (London) 2002, 415, 530-536.
17. Ghadimi, B. M.; Grade, M.; Difilippantonio, M. J. et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J. Clin. Oncol. 2005, 23, 1826-1838.
18. van't Veer, L. J.; Paik, S.; Hayes, D. F. Gene expression profiling of breast cancer, a new tumor marker. J. Clin. Oncol. 2005, 23, 1631-1635.
19. Mintz, M. B.; Sowers, R.; Brown, K. M. et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005, 65, 1748-1754.
20. Ramaswamy, S.; Ross, K. N.; Lander, E. S.; Golub, T. R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 2003, 33, 49-54.
21. Hao, X.; Sun, B.; Hu, L. et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 2004, 100, 1110-1122.
22. Eckhardt, B. L.; Parker, B. S.; van Laar, R. K. et al. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol. Cancer Res. 2005, 3, 1-13.
23. Yamashita, K.; Upadhay, S.; Mimori, K.; Inoue, H.; Mori, M. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer 2003, 97, 2412-2419.
24. Gilles, C.; Bassuk, J. A.; Pulyaeva, H. et al. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 1998, 58, 5529-5536.
25. Dankort, D. L.; Muller, W. J. Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene 2000, 19, 1038-1044.
26. Lifsted, T.; Le Voyer, T.; Williams, M et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int. J. Cancer 1998, 77, 640-644.
27. Verrecchia, F.; Chu, M. L.; Mauviel, A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J. Biol. Chem. 2001, 276, 17058-17062.
28. Bhattacharjee, A.; Richards, W. G.; Staunton, J. et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 13790-13795.
29. Huang, M.; Dorsey, J. F.; Epling-Burnette, P. K. et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 2002, 21, 8804-8816.
30. Birkenkamp, K. U.; Geugien, M.; Lemmink, H. H.; Kruijer, W.; Vellenga, E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 2001, 15, 1923-1931.
31. Li, H.; Ahonen, T. J.; Alanen, K. et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res. 2004, 64, 4774-4782.
32. Kazansky, A. V.; Spencer, D. M.; Greenberg, N. M. Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res. 2003, 63, 8757-8762.
33. Edwards, G. M.; Wilford, F. H.; Liu, X. et al. Regulation of Mammary Differentiation by Extracellular Matrix Involves Protein-tyrosine Phosphatases. J. Biol. Chem. 1998, 273, 9495-9500.
34. Yu, H.; Jove, R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 2004, 4, 97-105.
35. Widschwendter, A.; Tonko-Geymayer, S.; Weite, T. et al. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin. Cancer Res. 2002, 8, 3065-3074.
36. Thomas, M.; Finnegan, C. E.; Rogers, K. M. A. et al. STAT1: A Modulator of Chemotherapy-induced Apoptosis. Cancer Res. 2004, 64, 8357-8364.
37. Foukas, L. C.; Daniele, N.; Ktori, C. et al. Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J. Biol. Chem. 2002, 277, 37124-37130.
38. Franke, T. F.; Hornik, C. P.; Segev, L.; Shostak, G. A.; Sugimoto, C. PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22, 8983-8998.
39. Hutchinson, J.; Jin, J.; Cardiff, R. D.; Woodgett, J. R.; Muller, W. J. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol. Cell. Biol. 2001, 21, 2203-2212.
40. Holland, E. C.; Celestino, J.; Dai, C. et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 2000, 25, 55-57.
41. Perez-Tenorio, G.; Stal, O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer 2002, 86, 540-545.
42. Hutchinson, J. N.; Jin, J.; Cardiff, R. D.; Woodgett, J. R.; Muller, W. J. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. 2004, 64, 3171-3178.